Compare AbbVie Inc (ABBV) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs TG Therapeutics Inc — how do they compare? AbbVie Inc trades at $254.08 (market cap $449.91B), while TG Therapeutics Inc trades at $56.67 (market cap $8.89B). The key difference: AbbVie Inc is far larger — about 50.6× TG Therapeutics Inc's market cap, and AbbVie Inc pays a 2.72% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABBV | TGTX | |
|---|---|---|
Market Cap | $449.91B | $8.89B |
Sector | Health | Health |
52-Week High | $261.07 | $58.06 |
52-Week Low | $184.85 | $26.39 |
Enterprise Value | $513.38B | $9.13B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
TGTX trades at $55.47, up 4.05% today, with a bullish technical signal from moving averages and strong fundamental profitability. Revenue grew to $616.29M in 2025 with a net income margin of 65.95%, though recent quarterly EPS missed expectations. Positive news includes a new Phase II study for Briumvi in schizophrenia and strong sales momentum.
Outlook is positive driven by Briumvi's expansion, but risks include clinical trial outcomes and earnings volatility. Analysts are bullish with 84.6% buy ratings. The stock's high valuation multiples warrant monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
